Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nortriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nortriptyline SCHEMBL29362430 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL34527 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL41329 | 0.98 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29751879 | 0.98 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7158809 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7092935 | 0.97 | LMNA (0.94) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL2244623 | 0.97 | SLC6A2 (0.94) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Amitriptyline SCHEMBL3897883 | 0.90 | SLC6A2 (0.81) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL21859431 | 0.89 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL22147029 | 0.89 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3191105-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | Braintree Laboratories, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040733-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | BRAINTREE LABORATORIES, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2012048243-A2 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2254564-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | Glaxo Group Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009074607-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1981524-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007092616-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276404-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | SLC6A2 3027/4885SLC6A4 2567/4885HRH1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.